Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.39 |
| ▸ | CBFB | Q13951 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198944 | 0.79 | L3MBTL1 (0.34) | MAPTALDH1A1KDM4ECA12CA1 | |
| SCHEMBL27614756 | 0.73 | — | — | |
| SCHEMBL1415869 | 0.72 | L3MBTL1 (0.44) | ALDH1A1CA2 | |
| SCHEMBL3453513 | 0.71 | CA1 (0.40) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL4491981 | 0.71 | MAPT (0.41) | MAPTALDH1A1GAAHPGDHTT | |
| SCHEMBL1416134 | 0.70 | L3MBTL1 (0.46) | ALDH1A1CA2 | |
| SCHEMBL4196642 | 0.69 | MAPT (0.65) | MAPTALDH1A1HPGDKDM4ECA12 | |
| SCHEMBL7425685 | 0.68 | ALDH1A1 (0.50) | MAPTALDH1A1GAAHPGDHTT | |
| SCHEMBL7425364 | 0.68 | HDAC3 (0.49) | MAPTHTTKDM4ECA12CA1 | |
| SCHEMBL7425945 | 0.68 | MKNK1 (0.55) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | MAPT 2289/4885ALDH1A1 3435/4885GAA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.